Phyo Aung Zaw Zaw, Espinoza Sara E, Orchard Suzanne G, Wolfe Rory, Murray Anne M, Woods Robyn L, Ryan Joanne
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.
Center for Translational Geroscience, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States.
J Gerontol A Biol Sci Med Sci. 2025 Sep 10. doi: 10.1093/gerona/glaf198.
Grip strength and gait speed are key markers of physical functional capacity and general health in older people. This study aimed to examine the effect of low-dose aspirin on hand-grip strength and habitual gait speed in relatively healthy older people.
The ASPREE (ASPirin in Reducing Events in the Elderly) trial randomized 19,114 community-dwelling Australians and U.S. adults aged 70+ years (U.S. minorities ≥65 years) who were free of overt cardiovascular disease, dementia and limitations in activities of daily living to daily 100 mg aspirin versus placebo. Linear mixed models were used to compare the effects of treatment groups on changes in grip strength and gait speed over time, and Cox proportional hazard models were used to compare time to incident grip weakness and gait slowness between aspirin and placebo groups.
Over a median of 4.7 years, the changes in grip strength (Beta: 0.001; 95% CI: -0.004 to 0.005) and gait speed (Beta: -0.004; 95% CI: -0.010 to 0.001) did not differ significantly between aspirin and placebo groups. Over the study period, 6203 participants experienced incident grip weakness, and 6947 had incident gait slowness. There was no difference in the risk of incident grip weakness (HR: 1.05; 95% CI: 1.00, 1.10) and gait slowness (HR: 1.00; 95% CI: 0.95, 1.05) between individuals randomized to aspirin versus placebo.
Low-dose aspirin use in relatively healthy older people did not affect gait speed or grip strength over time or reduce the risk of weakness and slowness.
握力和步速是老年人身体功能能力和总体健康的关键指标。本研究旨在探讨低剂量阿司匹林对相对健康的老年人握力和习惯性步速的影响。
阿司匹林减少老年人事件（ASPREE）试验将19114名年龄在70岁及以上（美国少数族裔≥65岁）、无明显心血管疾病、痴呆且日常生活活动无限制的澳大利亚和美国社区居民随机分为两组，一组每日服用100毫克阿司匹林，另一组服用安慰剂。采用线性混合模型比较治疗组对握力和步速随时间变化的影响，采用Cox比例风险模型比较阿司匹林组和安慰剂组出现握力减弱和步速减慢的时间。
在中位数为4.7年的时间里，阿司匹林组和安慰剂组在握力变化（β：0.001；95%置信区间：-0.004至0.005）和步速变化（β：-0.004；95%置信区间：-0.010至0.001）方面无显著差异。在研究期间，6203名参与者出现握力减弱，6947名参与者出现步速减慢。随机分配到阿司匹林组和安慰剂组的个体在出现握力减弱风险（风险比：1.05；95%置信区间：1.00，1.10）和步速减慢风险（风险比：1.00；95%置信区间：0.95，1.05）方面无差异。
相对健康的老年人使用低剂量阿司匹林不会随时间影响步速或握力，也不会降低出现虚弱和步速减慢的风险。
